The invention includes stable non-infectious cell clones that produce autonomously replicating severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) RNAs except the Spike (S), Matrix (M), and Envelope (E) genes. These cell clones are useful for screening candidate direct-acting antiviral drugs (DAAs) and studying the genetic and function aspects of SARS-coV-2 replication. These cell clones are derived from baby hamster kidney cells (BHK-21 cells). A pair of mutations have been introduced into non-structural protein 1 gene (NSP-1) to ameliorate cellular toxicity associated with viral replication. These clones can be used to screen antivirals and study coronavirus replication in a biosafety level 2 (BSL-2) laboratory.
The SARS-CoV-2 virus causes COVID-19 and is responsible for the recent pandemic. Vaccines have been approved to prevent COVID-19, but there remains a need for effective antivirals to treat COVID-19. This cell-based system is an improvement over currently known cell-based systems that replicate Sars-coV-2 RNA because it is self-replicating and viral RNA replication is not toxic to the host-cell. This cell clone can be maintained in culture and does not need to be produced prior to experiments. Additionally, the stability of this clone permits screening over longer time periods.
|Potential Commercial Applications||Competitive Advantages|
Development Stage: Proof-of-concept for screening compounds, Research Tool
Inventors: Tony T. Wang, Shufeng Liu
Publications: Shufeng Liu, et. al., Stable Cell Clones Harboring Self-Replicating SARS-CoV-2 RNAs for Drug Screen, 2021 Nov. 8; Preprint; doi: https://doi.org/10.1101/2021.11.04.467291 (viewed at https://www.biorxiv.org/content/10.1101/2021.11.04.467291v1.full on Nov. 23, 2021).
Intellectual Property: A U.S. provisional application has been filed
Product Area: COVID-19, Sars-CoV-2, Antiviral Drugs, Screening
FDA Reference No: E-2021-017
FDA Technology Transfer Program